NCT01586442

Comparison of Eplerenone Versus Spironolactone in Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes

A Comparison of the Effects of Selective and Non Selective Mineralocorticoid Antagonism on Glucose Homeostasis and Lipid Profile of Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 62 (actual)
• Sponsor: Montreal Heart Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this proposal,the investigators will examine whether the selectivity of eplerenone for the MR will translate into a better glucose and metabolic profile compare to spironolactone in patients with HF with glucose intolerance or type 2 diabetes. In addition, the investigators will also compare the impact of these two agents on changes of concentrations of established prognostic biomarkers of neurohormonal activation and extracellular matrix turnover.

Conditions

• Heart Failure
• Type 2 Diabetes
• Glucose Intolerance

Interventions

Type	Name	Description
DRUG	Eplerenone	Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
DRUG	Spironolactone	Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks

Timeline

• Start date: 2012-03-01
• Primary completion: 2015-03-01
• Completion: 2018-07-29
• First posted: 2012-04-26
• Last updated: 2022-10-07

Locations

1 site across 1 country: Canada